Pancreas transplantation: The Wake Forest experience in the new millennium

作     者：Jeffrey Rogers Alan C Farney Giuseppe Orlando Samy S Iskandar William Doares Michael D Gautreaux Scott Kaczmorski Amber Reeves-Daniel Amudha Palanisamy Robert J Stratta 

作者机构：Department of General SurgeryWake Forest Baptist Medical CenterWinston Salem Department of PathologyWake Forest Baptist Medical CenterWinston-Salem Department of PharmacyWake Forest Baptist Medical CenterWinston-Salem Department of Internal Medicine (Nephrology)Wake Forest Baptist Medical CenterWinston-Salem 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2014年第5卷第6期

页      面：951-961页

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

主　　题：Alemtuzumab Mycophenolate mofetil Pancreas transplantation Portal-enteric Rabbit anti-thymocyte globulin Simultaneous kidney-pancreas transplantation Solitary pancreas transplantation Steroid elimination Surveillance biopsy Tacrolimus 

摘      要：AIM: To investigate the Wake Forest experience with pancreas transplantation in the new millennium with attention to surgical techniques and immunosuppression. METHODS: A monocentric, retrospective review of outcomes in simultaneous kidney-pancreas transplant(SKPT) and solitary pancreas transplant(SPT) recipients was performed. All patients underwent pancreas transplantation as intent-to-treat with portal venous and enteric exocrine drainage and received depleting antibody induction; maintenance therapy included tapered steroids or early steroid elimination with my-cophenolate and tacrolimus. Recipient selection was based on clinical judgment whether or not the patient exhibited measureable levels of C-peptide. RESULTS: Over an 11.25 year period, 202 pancreas transplants were performed in 192 patients including 162 SKPTs and 40 SPTs. A total of 186(92%) were primary and 16(8%) pancreas retransplants; portalenteric drainage was performed in 179 cases. A total of 39 pancreas transplants were performed in African American(AA) patients; of the 162 SKPTs, 30 were performed in patients with pretransplant C-peptide levels 2.0 ng/m L. In addition, from 2005-2008, 46 SKPT patients were enrolled in a prospective study of single dose alemtuzumab vs 3-5 doses of rabbit antithymocyte globulin induction therapy. With a mean follow-up of 5.7 in SKPT vs 7.7 years in SPT recipients, overall patient(86% SKPT vs 87% SPT) and kidney(74% SKPT vs 80% SPT) graft survival rates as well as insulin-free rates(both 65%) were similar(P = NS). Although mortality rates were nearly identical in SKPT compared to SPT recipients, patterns and timing of death were different as no early mortality occurred in SPT recipients whereas the rates of mortality following SKPT were 4%, 9% and 12%, at 1-, 3- and 5-years follow-up, respectively(P 0.05). The primary cause of graft loss in SKPT recipients was death with a functioning graft whereas the major cause of graft loss following SPT was acute and